Cybin submits application for trial of psilocybin-based CYB003 to treat depression
seekingalpha.com
finance
2022-05-31 13:45:05

May 31, 2022 9:45 AM ETCybin, Inc. (CYBN)By: Anuron Mitra, SA News Editor xijian/E+ via Getty Images Cybin (NYSE:CYBN) on Tuesday said it had submitted an investigational new drug application to the U.S. Food and Drug Administration for a phase 1/2a trial to evaluate its psilocybin derived therapy CYB003 for the treatment of depression. Psilocybin is the psychedelic active compound in magic mushrooms. Several biotech companies have been looking into its use as a treatment for major depressive disorder (MDD).
